Business Wire

TX-MARY-KAY

Share
Mary Kay Inc. Recommits to Responsible and Sustainable Water Management Following World Water Day 2022

Water is essential to life in all its forms and to the ongoing development of a healthy and sustainable future. According to the World Economic Forum , environmental risks and the impact on natural ecosystems and resources continues to be a top global risk.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220324005126/en/

This World Water Day, Mary Kay Inc. recommits to responsible and sustainable water management to ensure the ongoing availability of water as an essential resource to meet the needs of the environment and communities around the world.

Water is at the heart of Mary Kay’s sustainability strategy and crucial to its manufacturing processes. Implementing good water stewardship principles is critical for Mary Kay to reach our sustainability goals. We strive to ensure water use for human and economic needs does not disrupt sustainable water cycles or cause ongoing harm to nature and biodiversity. Recent water efforts at Mary Kay facilities include:

  • Water use at U.S. Mary Kay-owned facilities decreased 36% from 2012-2017.
  • At Mary Kay’s manufacturing facility in Hangzhou, China, significant strides toward water conservation include:
    • Reduced potable water use by 34%, which saves approximately 913,480 gallons of potable water per year.
    • Reverse Osmosis (RO) reject water reuse: The purifying water equipment produces a large amount of concentrated water discharge in the operation process. By collecting concentrated water and passing it through the circulation system, concentrated water will be reused through the fire tower and air-cooling tower system as a supplementary water source.
    • Wastewater treatment upgrade: To mitigate the environmental impact of wastewater in its manufacturing processes, Mary Kay China invested in an advanced membrane bioreactor (MBR) process using existing infrastructure to improve the capacity of wastewater treatment and reduce sludge discharge by 40%.

“As a global sustainability advocate, Mary Kay is dedicated to playing an important role in collective efforts to cause no harm to the environment and to ensure communities and economies prosper,” said Deborah Gibbins , Chief Operating Officer at Mary Kay Inc. “Mary Kay will continue to build upon its progress and work toward its commitment of reducing water utilization in our manufacturing processes by 30% by the year 2030 versus a 2020 baseline per kilogram bulk produced. Achieving Alliance for Water Stewardship (AWS) Core Certification for Mary Kay manufacturing facilities in the U.S. and China will help move us closer to our goals.”

Several key components of Mary Kay’s decade of action include:

  • A current signatory of the UN Ocean Principles and CEO Water Mandate.
  • Continuing its 32-year partnership with The Nature Conservancy and supporting 11 global water projects in 2022 focusing on:
    • Global ocean protection to improve ocean health for nature and people;
    • Restoring Asia Pacific Shellfish Reefs in Australia, Hong Kong, China, the Coral Triangle, and the Cakaulevu Reef (also called the Great Sea Reef);
    • Supporting Women Leaders in The Pacific in Papua New Guinea (Mangroves, Women, and Markets) and the Solomon Islands (Community Health and Resilience);
    • Coastal Conservation and Restoration in the Gulf Coast (Protecting the Gulf Coast Coastal Wetlands);
    • Improving Fisheries in Mexico (Improving Fisheries and Empowering Communities); and
    • Collaborating with partners in Europe supporting native oyster restoration projects in England, Scotland, Ireland, France, the Netherlands, Germany, and Sweden.
  • Joining Alliance for Water Stewardship and working to achieve certification of our two manufacturing facilities by 2025.

To read more about Mary Kay’s commitment to sustainability, visit marykayglobal.com/sustainability and download Mary Kay’s global sustainability strategy, Enriching Lives Today for a Sustainable Tomorrow.

About Mary Kay Inc.

One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey to economic independence through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com , find us on Facebook , Instagram , and LinkedIn or follow us on Twitter .

About The Nature Conservancy

The Nature Conservancy is a global conservation organization dedicated to conserving the lands and waters on which all life depends. Guided by science, we create innovative, on-the-ground solutions to our world's toughest challenges so that nature and people can thrive together. We are tackling climate change, conserving lands, waters and oceans at an unprecedented scale, providing food and water sustainably and helping make cities more sustainable. Working in 79 countries and territories, we use a collaborative approach that engages local communities, governments, the private sector, and other partners. To learn more, visit www.nature.org or follow @nature_press on Twitter.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye